Literature DB >> 29549977

Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.

Taylor T Chrisikos1, Yifan Zhou2, Natalie Slone3, Rachel Babcock1, Stephanie S Watowich4, Haiyan S Li5.   

Abstract

Dendritic cells (DCs) are the principal antigen-presenting cells of the immune system and play key roles in controlling immune tolerance and activation. As such, DCs are chief mediators of tumor immunity. DCs can regulate tolerogenic immune responses that facilitate unchecked tumor growth. Importantly, however, DCs also mediate immune-stimulatory activity that restrains tumor progression. For instance, emerging evidence indicates the cDC1 subset has important functions in delivering tumor antigens to lymph nodes and inducing antigen-specific lymphocyte responses to tumors. Moreover, DCs control specific therapeutic responses in cancer including those resulting from immune checkpoint blockade. DC generation and function is influenced profoundly by cytokines, as well as their intracellular signaling proteins including STAT transcription factors. Regardless, our understanding of DC regulation in the cytokine-rich tumor microenvironment is still developing and must be better defined to advance cancer treatment. Here, we review literature focused on the molecular control of DCs, with a particular emphasis on cytokine- and STAT-mediated DC regulation. In addition, we highlight recent studies that delineate the importance of DCs in anti-tumor immunity and immune therapy, with the overall goal of improving knowledge of tumor-associated factors and intrinsic DC signaling cascades that influence DC function in cancer.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antigen presentation; Cytokine; Dendritic cell; Molecular regulation; STAT; Tumor

Mesh:

Year:  2018        PMID: 29549977      PMCID: PMC6139080          DOI: 10.1016/j.molimm.2018.01.014

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  249 in total

Review 1.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

2.  Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors:  Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

3.  GM-CSF increases cross-presentation and CD103 expression by mouse CD8⁺ spleen dendritic cells.

Authors:  Yifan Zhan; Emma M Carrington; Annemarie van Nieuwenhuijze; Sammy Bedoui; Shirley Seah; Yuekang Xu; Nancy Wang; Justine D Mintern; Jose A Villadangos; Ian P Wicks; Andrew M Lew
Journal:  Eur J Immunol       Date:  2011-08-04       Impact factor: 5.532

4.  Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand.

Authors:  E Daro; B Pulendran; K Brasel; M Teepe; D Pettit; D H Lynch; D Vremec; L Robb; K Shortman; H J McKenna; C R Maliszewski; E Maraskovsky
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

5.  The signal transducers STAT5 and STAT3 control expression of Id2 and E2-2 during dendritic cell development.

Authors:  Haiyan S Li; Cliff Y Yang; Kalyan C Nallaparaju; Huiyuan Zhang; Yong-Jun Liu; Ananda W Goldrath; Stephanie S Watowich
Journal:  Blood       Date:  2012-10-01       Impact factor: 22.113

6.  The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells.

Authors:  Terry K Means; Fumitaka Hayashi; Kelly D Smith; Alan Aderem; Andrew D Luster
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

7.  Bypassing STAT3-mediated inhibition of the transcriptional regulator ID2 improves the antitumor efficacy of dendritic cells.

Authors:  Haiyan S Li; Chengwen Liu; Yichuan Xiao; Fuliang Chu; Xiaoxuan Liang; Weiyi Peng; Jianhua Hu; Sattva S Neelapu; Shao-Cong Sun; Patrick Hwu; Stephanie S Watowich
Journal:  Sci Signal       Date:  2016-09-27       Impact factor: 8.192

8.  Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD.

Authors:  Christian M Capitini; Nicole M Nasholm; Christopher D Chien; Shannon M Larabee; Haiying Qin; Young K Song; Peter J Klover; Lothar Hennighausen; Javed Khan; Terry J Fry
Journal:  Blood       Date:  2014-07-25       Impact factor: 22.113

Review 9.  Diversification of dendritic cell subsets: Emerging roles for STAT proteins.

Authors:  Haiyan S Li; Stephanie S Watowich
Journal:  JAKSTAT       Date:  2013-05-21

10.  STAT2 hypomorphic mutant mice display impaired dendritic cell development and antiviral response.

Authors:  Lan-Sun Chen; Pei-Chi Wei; Taming Liu; Chung-Hsuan Kao; Li-Mei Pai; Chien-Kuo Lee
Journal:  J Biomed Sci       Date:  2009-02-19       Impact factor: 8.410

View more
  15 in total

1.  Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes.

Authors:  Chunmei Fu; Peng Peng; Jakob Loschko; Li Feng; Phuong Pham; Weiguo Cui; Kelvin P Lee; Anne B Krug; Aimin Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-02       Impact factor: 11.205

2.  The enhancing effects of Biobran/MGN-3, an arabinoxylan rice bran, on healthy old adults' health-related quality of life: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  A F Elsaid; R M Fahmi; M Shaheen; M Ghoneum
Journal:  Qual Life Res       Date:  2019-09-05       Impact factor: 4.147

Review 3.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

4.  STAT3 Contributes to Intracranial Aneurysm Formation and Rupture by Modulating Inflammatory Response.

Authors:  Zhixian Jiang; Jiaxin Huang; Lingtong You; Jinning Zhang; Bingyu Li
Journal:  Cell Mol Neurobiol       Date:  2020-08-17       Impact factor: 5.046

5.  Evolution and Potential Subfunctionalization of Duplicated fms-Related Class III Receptor Tyrosine Kinase flt3s and Their Ligands in the Allotetraploid Xenopus laevis.

Authors:  Matthieu Paiola; Siyuan Ma; Jacques Robert
Journal:  J Immunol       Date:  2022-08-05       Impact factor: 5.426

6.  STAT3 Inhibits Autocrine IFN Signaling in Type I Conventional Dendritic Cells.

Authors:  Taylor T Chrisikos; Yifan Zhou; Laura M Kahn; Bhakti Patel; Nina L Denne; Athena Brooks; Li Shen; Jing Wang; Stephanie S Watowich
Journal:  J Immunol       Date:  2022-08-29       Impact factor: 5.426

7.  Pathogen-Boosted Adoptive Cell Transfer Therapy Induces Endogenous Antitumor Immunity through Antigen Spreading.

Authors:  Gang Xin; Achia Khatun; Paytsar Topchyan; Ryan Zander; Peter J Volberding; Yao Chen; Jian Shen; Chunmei Fu; Aimin Jiang; William A See; Weiguo Cui
Journal:  Cancer Immunol Res       Date:  2019-11-12       Impact factor: 11.151

8.  Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells.

Authors:  Yifan Zhou; Natalie Slone; Taylor T Chrisikos; Oleksandr Kyrysyuk; Rachel L Babcock; Yusra B Medik; Haiyan S Li; Eugenie S Kleinerman; Stephanie S Watowich
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

9.  Absence of GdX/UBL4A Protects against Inflammatory Diseases by Regulating NF-кB Signaling in Macrophages and Dendritic Cells.

Authors:  Chunxiao Liu; Yifan Zhou; Mengdi Li; Ying Wang; Liu Yang; Shigao Yang; Yarui Feng; Yinyin Wang; Yangmeng Wang; Fangli Ren; Jun Li; Zhongjun Dong; Y Eugene Chin; Xinyuan Fu; Li Wu; Zhijie Chang
Journal:  Theranostics       Date:  2019-02-14       Impact factor: 11.556

10.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.